Skip to content

Hydration therapy in preterm jaundice

Extra Fluid supplementation in management of unconjugated hyperbilirubinemia in preterm neonates-A randomized controlled trial. - nil

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/01/061381
Enrollment
72
Registered
2024-01-11
Start date
Unknown
Completion date
Unknown
Last updated
2024-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P590- Neonatal jaundice associated withpreterm delivery

Interventions

Intervention1: EXTRA FLUID THERAPY: Received extra fluid volume- one fourth of maintenance fluid (maximum: 30 ml/kg/day) either 5% dextrose at 24-48h or N/5 5% dextrose after 48h over 12-hour intra ve

Sponsors

Aradhana
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Preterm neonate (29-33 +6) with severe unconjugated hyperbilirubinemia during first two weeks of life.

Exclusion criteria

Exclusion criteria: Jaundice 40%, symptomatic PDA or CHD, neonatal encephalopathy, TSB level above 5mg/dl of exchange transfusion threshold

Design outcomes

Primary

MeasureTime frame
Compare the decline in serum bilirubin level at 6 hourly,18 hourly & then every 12 hourly in both groups.Timepoint: 6th hourly, 18th hourly and then every 12th hourly till S. Bilirubin is below cut off for phototherapy.

Secondary

MeasureTime frame
Compare the need of exchange transfusion, bilirubin induced encephalopathy & possible clinical effect of extra fluid supplementation such as, weight gain, increased oxygen requirement, derangement in serum sodium level, need of extra intravenous line, opening of Patent ductus arteriosus in both arms.Timepoint: 4 hours after starting phototherapy

Countries

India

Contacts

Public ContactAradhana

KALINGA INSTITUTE OF MEDICAL SCIENCES

doc.sant@yahoo.co.in9778182963

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 5, 2026